Literature DB >> 8294987

High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET.

C Messa1, D Perani, G Lucignani, A Zenorini, F Zito, G Rizzo, F Grassi, A Del Sole, M Franceschi, M C Gilardi.   

Abstract

UNLABELLED: SPECT studies of regional cerebral perfusion with a high-resolution system were compared to PET studies of regional cerebral glucose utilization (rCMRglc) in 21 patients with probable Alzheimer's disease (AD). Ten normal subjects were also evaluated with SPECT and 10 with PET.
METHODS: rCMRglc (for PET) and counts (for SPECT) in the associative cortices were normalized to the average rCMRglc, and counts in the calcarine cortex and basal ganglia were considered as a "reference area" to obtain a ratio. The ratio differences between patients and controls were tested with ANOVA performed separately for PET and SPECT.
RESULTS: The difference between probable AD patients and controls was significant for both PET (p < 0.00001) and SPECT (p < 0.005); this difference was significant for the frontal, temporal and parietal cortices (p < 0.0001) for PET, and for the temporal (p < 0.005) and parietal (p < 0.001) cortices for SPECT. Temporo-parietal defects were detected in all subjects with PET and in 90% with SPECT.
CONCLUSION: PET and SPECT are able to detect characteristic temporo-parietal abnormalities in probable AD. However, the presence of abnormalities in other associative areas is better evaluated with PET.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8294987

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  24 in total

Review 1.  A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile.

Authors:  Konstantine K Zakzanis; Simon J Graham; Zachariah Campbell
Journal:  Neuropsychol Rev       Date:  2003-03       Impact factor: 7.444

2.  Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow.

Authors:  Bich-Ngoc-Thanh Tang; Satoshi Minoshima; Jean George; Annie Robert; Christian Swine; Patrice Laloux; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

3.  Empirical derivation of the reference region for computing diagnostic sensitive ¹⁸fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample.

Authors:  Jerod M Rasmussen; Anita Lakatos; Theo G M van Erp; Frithjof Kruggel; David B Keator; James T Fallon; Fabio Macciardi; Steven G Potkin
Journal:  Biochim Biophys Acta       Date:  2011-09-19

4.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.

Authors:  Alberto Pupi; Flavio Mariano Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

5.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- for.

Authors:  Kazunari Ishii; Satoshi Minoshima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

6.  Brain SPET perfusion in early Alzheimer's disease: where to look?

Authors:  Ingeborg Goethals; Christophe Van De Wiele; Daniel Slosman; Rudi Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08       Impact factor: 9.236

7.  Cerebral perfusion and psychometric testing in military amateur boxers and controls.

Authors:  P M Kemp; A S Houston; M A Macleod; R J Pethybridge
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-10       Impact factor: 10.154

8.  An elastic computerized brain atlas for the analysis of clinical PET/SPET data.

Authors:  G Rizzo; M C Gilardi; A Prinster; F Grassi; G Scotti; S Cerutti; F Fazio
Journal:  Eur J Nucl Med       Date:  1995-11

Review 9.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 10.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.